Thomas A. Raffin, Senior Partner/Co-Founder, at Telegraph Hill Partners, San Francisco, California. See sector focus and contact routes.
Thomas A. Raffin is the Senior Partner and Co-Founder of Telegraph Hill Partners, a San Francisco-based life sciences growth equity firm he established in 2001, complementing his 28-year career as Professor Emeritus of Medicine at Stanford University. His investment thesis targets later-stage life sciences companies in the United States, with specific focus on medical devices, diagnostics, therapeutics, and health services. Typical investment checks range from $100,000 to $5.0 million, leveraging his deep medical expertise to guide ventures before strategic sale. Notable portfolio companies include Akoya Biosciences and Lumos Pharma, where he serves on the boards, alongside his founding of Rigel Pharmaceuticals in 1996. Raffin distinguishes himself by sourcing and building companies in life sciences and medical technology before their sale to strategic partners, drawing on prior experience as Co-Director of Stanford’s Intensive Care Unit. He also contributes to the Gladstone Foundation as a board director and serves as Co-Chair of the National AIDS Memorial, reflecting his commitment to biomedical research and philanthropy.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in San Francisco.
Investors like Thomas A. Raffin · Full investor directory · Investor access · Company funding database